Media Coverage

Gene therapy faces complexities in delivering treatments due to persistent safety concerns and daunting immune responses, but Next Generation Gene Therapeutics Inc. (NGGT) has found a way around this issue... read more →

For some genetic diseases, there is not only the need to replace the function of a gene that is lost, but to also address toxicities that a mutated gene may... read more →

In this podcast episode, the company's Co-Founder and Chief Operating Officer, Guang Qu, discusses how the company's dual-functional vector tech platform is being used to target many diseases.

During the course of conducting interviews, attending conferences and providing other coverage across the region, Scrip‘s on-the-ground team in APAC often hears comments and views that are worth highlighting by themselves,... read more →

Guang Qu, Co-Founder of NGGT Corporation is focused on developing gene therapy products using dual functional vector strategies. Guang highlights the importance of distinguishing between recessive and dominant mutations in... read more →

Last month, May 2024, the CGTLive® team was diligently tracking the latest data readouts and published literature on cell and gene therapies within oncology, ophthalmology, and rare diseases.

For global developers of rare disease drugs, China and its 1.4 billion population may offer relatively large pools of patients with such disorders. Clinical data derived from trials in the... read more →

Next Generation Gene Therapeutics (NGGT) Biotechnology’s NGGT001, an investigational adeno-associated virus (AAV) vector-based gene therapy intended to treat Bietti’s crystalline corneoretinal dystrophy (BCD), improved the vision of patients treated in... read more →